×

RNS Number : 4551H

N4 Pharma PLC

25 March 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").

 

25 March 2020

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Covid-19 Project Update and operational update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it will be undertaking a proof of concept research project using a Covid-19 DNA plasmid for the purpose of demonstrating the ability of Nuvec® to be used as a delivery system by potential collaboration partners developing Covid-19 DNA or RNA vaccines.

 

Nuvec® is a silica nanoparticle with elongated silica spikes radiating from the core.  This topography results in a high surface area which subsequently is coated with Polyethylenimine ("PEI"), resulting in a positively charged surface. It has been previously demonstrated that oligonucleotides including plasmid DNA and mRNA can be attached to the nanoparticle at high loading capacity. In both in vitro and in vivo test models, the loaded nanoparticle is taken up by cells involved in transfection/transduction processes resulting in the synthesis of foreign proteins and stimulation of the required immunological response.

The proof of concept work will show whether Nuvec® is capable of loading the Covid-19 plasmid and transfecting cells with the plasmid in vitro. Assuming successful in vitro transfection, the Company will then undertake a proof of concept in vivo study to demonstrate the improved transfection when using Nuvec ®, compared to not using the delivery system, by measuring the production of the antigenic protein and antibodies generated against the encoded Covid-19 protein.

The Covid-19 DNA plasmid will be licensed from the National Institute for Health (NIH) in the USA and is the same plasmid provided to leading biotech companies and researchers already working on Covid-19 vaccines. The Company will appoint an experienced contract research organisation (CRO) that it has worked with previously to undertake the program of studies outlined above. Further details on timings will be notified as soon as they are available. It is important to note that N4 Pharma is not itself attempting to develop a vaccine for coronavirus, it is purely seeking to demonstrate whether Nuvec ® could work as a delivery system for a vaccine when it is developed.

 

Operational impact of Covid-19 pandemic

 

The Company operates a virtual model, so most of its workforce typically either work from home or in small offices. Therefore, operationally, the Company has not been affected to date by the UK Government's requirements regarding social distancing and self-isolation.

 

Further, the Company has received confirmation that the main laboratories contracted by N4 Pharma to undertake research and those identified as partners for the Covid-19 work detailed above are implementing rota systems to enable key laboratory staff to stay and work on projects. As a result, there are no current significant delays to N4 Pharma's announced work plan. This will be kept under close review in the coming months, as the situation evolves.

 

The Company's academic partner in Australia remains open, meaning N4 Pharma currently has a continued supply of Nuvec ® for its research needs.

 

On 20 March 2020, the Company's academic partner in the UK announced it will be closed until after Easter. As this is a longer-term project, looking at stability testing and efficacy proof of concept of a DNA plasmid loaded on Nuvec® the Company does not expect this closure to greatly impact their program of work.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Developing a convincing proof of concept data package for Nuvec® is a key priority for the Company so demonstrating whether Nuvec® is capable of loading a plasmid DNA for the Coronavirus provides an opportunity to show the versatility and potential for our Nuvec® delivery system, and to license Nuvec® to partners looking to develop vaccines for this virus.

 

We are not doing this work to develop a vaccine for Coronavirus but rather to demonstrate to those working on these vaccines how Nuvec® may enhance any vaccine and could be beneficial for subsequent vaccines they may be looking to develop for this Coronavirus or other viruses that may well surface in the future."

 

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: +44(0)203 328 5656
Scott PR Georgia Smith	Tel: +44(0)1477 539 539

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDJIMRTMTMTBPM

Close

×

RNS Number : 3538G

British Honey Company PLC (The)

17 March 2020

 

17 March 2020

The British Honey Company

("BHC" the "Company")

 

HMRC authorisation to produce denatured alcohol

 

The British Honey Company, the premium British Honey and Infused Spirits brand, announces that it has received permission from HMRC to produce denatured alcohol and will now utilise its excess capacity to produce alcohol sanitisers at its distillery following a national shortage of alcohol based sanitiser products caused by the spread of Covid-19, coronavirus.

Additional capacity at the BHC distillery in Worminghall, Buckinghamshire, will be immediately used to make the alcohol sanitiser, with products expected to be available this week.  The specially formulated product is made with 70% alcohol and extracts of British Honey and Green Tea.

Michael Williams, Chief Executive Officer of BHC, commented: "An alcohol based sanitiser is vodka or gin at 70 percent ABV made from denatured alcohol.  Following approval of our application to HMRC to produce denatured alcohol, our expert distillery team have been working alongside our in-house microbiologist and an Oxford University chemist to develop and manufacture this new product.

"The Company will continue to produce its vodka, gin and rum products as the alcohol market moves to online sales in the current environment. BHC is making the product available online. Being able to produce such an in demand product within our existing capabilities enhances our existing business model at the same time as assisting with the efforts to combat the spread of Covid-19."

 

Enquiries:

The British Honey Company	Tel: +44 (0)80 0368 7612
Michael Williams, Founder and CEO
Cairn Financial Advisers LLP (Aquis Stock Exchange Corporate Adviser)	Tel: +44 (0)20 7213 0880
Jo Turner / Liam Murray / Mark Rogers
Stanford Capital Partners (Broker)	Tel: +44 (0)20 3815 8880
Patrick Claridge / John Howes / Bob Pountney
IFC Advisory (PR)	Tel: +44 (0)20 3934 6630
Graham Herring / Florence Chandler

 

For further information, visit: www.britishhoney.co.uk

 

Notes to Editors

The British Honey Company is a UK based producer of spirits, honey and jams. It began trading in November 2014 initially focused on honey production and, later, expanding into honey infused spirits. The Company currently produces 13 honey products and 16 spirits including gin, vodka, rum and whiskey, many of which have won awards in the UK and abroad. These products are produced and stored in the Company ' s facilities in Worminghall, Buckinghamshire.

 

The Company ' s facilities provide it with a scalable platform from which the Directors plan to expand operations through organic growth and acquisition both in the UK and abroad. The Company has invested significantly in its infrastructure which includes, inter alia , a fully operational distillery with an electronic, computer-controlled, 1,000-litre capacity still and a bottling facility capable of processing the equivalent of approximately 1.5 million bottles per year. Further, the Company has developed proprietary software to manage the manufacturing process and sales which allows the Company, among other things, to trace single ingredients through to individual bottles of spirits or jars of honey. This meticulous approach has earned the Company accreditations from the Soil Association, for organic food certification, and from SALSA, for food safety. The Directors believe SALSA certification has only been awarded to approximately 39 producers of gin, vodka and whiskey in the UK.

 

As well as producing the Keepr ' s brand spirits, the distillery is an accredited, HMRC compliant, bonded warehouse for the storage of its own and third-party products. The Directors believe this provides the Company with significant financial and logistical advantages over many craft distilleries whilst also allowing it to provide an end-to-end distillation and bottling service to third party brands which it can do so within its existing spare capacity.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXFLFSRVAIRLII

Close

×

RNS Number : 3532G

Osirium Technologies PLC

17 March 2020

 

17 March 2020

RNS REACH

 

 

Osirium Technologies plc

("Osirium" or "Group")

 

Contract win with major regional Ambulance Service

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with a major regional UK Ambulance Service.

 

The new client has purchased a 60 month term license for 250 devices for the Osirium PAM platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules. Consultancy and training from Osirium Professional Services are included in the contract.

The Osirium PAM platform has been selected in a public sector tender bid as part of a sales initiative led jointly by Osirium and an approved reseller partner. The principal d rivers for the client on this project are securing and controlling access to the infrastructure by 3rd party contractors and vendors, implementing secure access for internal staff to privileged accounts, and managing service accounts in line with policy.  The client will be making full use of Osirium Task Automation to 'Shift Left' or delegate IT tasks to junior IT team members and free up senior IT staff to focus on complex projects.

 

David Guyatt, Chief Executive Officer, commented : "I am delighted that, in addition to Osirium being selected as the specialist PAM provider for NHS Trusts, we and our reseller partners are now expanding our customer range to include the ambulance services sector.  It is another illustration of the strength of Osirium functionality, in particular our task and process automation capabilities, combined with our UK presence and ease of deployment. These allow customers to automate key processes and securely delegate essential tasks in a way that drives real time and cost savings while ensuring maximum security."

 

 

–  Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah
Alma (Financial PR) Hilary Buchanan / Josh Royston / Kieran Breheny	Tel: +44 (0) 203 405 0205

 

Notes to Editors:

Osirium Technologies plc (AIM: OSI) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Security solutions. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

Osirium has defined and delivered what the Directors view as the next generation Privileged Access Management solution. Osirium's award-winning Privileged Task Management module further strengthens Privileged Account Security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers. Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched Privileged Process Automation, providing a highly-flexible platform for automating essential IT processes to set a new benchmark in IT Process Automation. This was followed by the launch of Privileged Endpoint Manager in December 2019, bringing the total portfolio to three complementary solutions.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016. For further information please visit www.osirium.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAJFMFTMTIBBIM

Close

×

RNS Number : 4972G

Sativa Group PLC

17 March 2020

 

Press Release

17 March 2020

 

 

 

Sativa Group Plc

 

("Sativa" or "the Company") 

 

Launch of cannabinoid cannabigerol (CBG) hand cleanser 

 

Sativa Group Plc [NEX: SATI], the UK's leading quoted CBD wellness and medicinal cannabis Group, has commenced production of a cannabigerol (CBG) and alcohol-based hand cleanser in response to the increased need for hand sanitation as a result of Covid-19.

 

Existing research and commercially available products show evidence that CBG is an effective antibacterial agent and is also believed to be effective in combatting MRSA, one of the most common hospital superbugs.  As the Company continues its research, other formats may become available as we work with our supply chain to source all necessary raw materials.  The hand cleanser is expected to be available for sale in approximately ten days, subject to the Company receiving packaging and labelling as planned. 

 

George Thomas, Managing Director of Sativa subsidiary Goodbody Botanicals, said: "CBG has already proven itself as impactful in terms of combatting germs and, when coupled with alcohol, makes it an ideal hand cleanser.  We are pleased to be able to supply what, we hope, will be a tool in combatting the spread of this virus."  

 

"The UK and the world is facing a health crisis and at Sativa, while we are continuing focus on making the highest quality products and building the UK's leading CBD Wellness brands, we have prioritized new product development to help people in this period", said Henry Lees-Buckley, CEO of the Sativa Group.  

 

 

–  Ends –

Media enquiries. 

Abchurch Communications Julian Bosdet +44 (0)207 4594 4070  +44 (0) 7771 663 886

[email protected] www.abchurch-group.com

 

For further information please contact: 

 

Henry Lees-Buckley  Chief Executive Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected] www.sativagroup.co.uk	Joseph Colliver Chief Financial Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected]   www.sativagroup.co.uk
NEX Exchange Corporate Adviser   Corporate Finance  Stephen Keys / Max Gould  Cenkos Securities plc  +44 (0) 20 7397 8900	Equity Sales  Julian Morse Cenkos Securities +44 (0) 20 7397 8900

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAMZGMFKNKGGZM

Close

×

RNS Number : 3532G

Osirium Technologies PLC

17 March 2020

 

17 March 2020

RNS REACH

 

 

Osirium Technologies plc

("Osirium" or "Group")

 

Contract win with major regional Ambulance Service

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with a major regional UK Ambulance Service.

 

The new client has purchased a 60 month term license for 250 devices for the Osirium PAM platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules. Consultancy and training from Osirium Professional Services are included in the contract.

The Osirium PAM platform has been selected in a public sector tender bid as part of a sales initiative led jointly by Osirium and an approved reseller partner. The principal d rivers for the client on this project are securing and controlling access to the infrastructure by 3rd party contractors and vendors, implementing secure access for internal staff to privileged accounts, and managing service accounts in line with policy.  The client will be making full use of Osirium Task Automation to 'Shift Left' or delegate IT tasks to junior IT team members and free up senior IT staff to focus on complex projects.

 

David Guyatt, Chief Executive Officer, commented : "I am delighted that, in addition to Osirium being selected as the specialist PAM provider for NHS Trusts, we and our reseller partners are now expanding our customer range to include the ambulance services sector.  It is another illustration of the strength of Osirium functionality, in particular our task and process automation capabilities, combined with our UK presence and ease of deployment. These allow customers to automate key processes and securely delegate essential tasks in a way that drives real time and cost savings while ensuring maximum security."

 

 

–  Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah
Alma (Financial PR) Hilary Buchanan / Josh Royston / Kieran Breheny	Tel: +44 (0) 203 405 0205

 

Notes to Editors:

Osirium Technologies plc (AIM: OSI) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Security solutions. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

Osirium has defined and delivered what the Directors view as the next generation Privileged Access Management solution. Osirium's award-winning Privileged Task Management module further strengthens Privileged Account Security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers. Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched Privileged Process Automation, providing a highly-flexible platform for automating essential IT processes to set a new benchmark in IT Process Automation. This was followed by the launch of Privileged Endpoint Manager in December 2019, bringing the total portfolio to three complementary solutions.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016. For further information please visit www.osirium.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAJFMFTMTIBBIM

Close

×

RNS Number : 1896G

British Honey Company PLC (The)

16 March 2020

 

16 March 2020

The British Honey Company

("BHC" the "Company")

ADMISSION TO TRADING AND FIRST DAY OF DEALINGS

BHC, the premium British Honey and Infused Spirits brand, is pleased to announce that admission of its shares to trading on the Aquis Stock Exchange Growth Market ("AQSE") will take place and dealings will commence at 8.00 a.m. today, under the ticker BHC and ISIN number GB00B64Q03333.

 

The oversubscribed placing with institutional investors raised gross proceeds of £4.25m at a placing price of 110 pence per share.  The proceeds will principally be used by the Company for working capital purposes, strengthening the balance sheet and funding selective acquisitions.

 

Investment Highlights

·	BHC has established and owns a number of spirit brands, including the award winning premium brand Keepr's with an established market presence through supermarkets (Waitrose, Majestic and Amazon) and specialist outlets (Not On The High Street, Masters of Malt and HT Drinks), differentiated through the development of new products and by using honey produced by the Company;
·	BHC has invested in a modern production facility including a distillery with a computer-controlled 1,000 litre still and bottling plant capable of producing approximately 1.5 million bottles per year at capacity;
·	BHC has a HMRC compliant bonded warehouse for the storage of its own and third-party products which the Directors believe provides significant cash flow and supply chain advantages over many smaller craft producers ;
·	BHC has built a bespoke, end-to-end IT platform capable of supporting the entire business, including full traceability of production from still and hive to bottle and jar;
·	BHC is one of the leading independent producers of natural British honey in the UK, producing around 7 tonnes of British honey per year;
·	the distillery is operated by the multi-award-winning master distiller, Jamie Baggott, who has developed the current range of products to meet evolving trends and demographics in the market;
·	BHC is run by a skilled and knowledgeable Board, with experience across the drinks sector and corporate finance , supported by a talented and driven management team;
·	the Directors believe the Company is well positioned to develop a buy and build strategy by acquiring other gin or spirit producers in a consolidating UK market;
·	it has a partnership with the Tusmore Estate where it maintains most of its hives and where it is intending to establish a whiskey distillery and bonded warehouse;
·	it has obtained the Safe and Local Supplier Approval ("SALSA") accreditation which ensures the highest quality of safety and assurance from all of the Company's products and manufacturing process; and
·	the Company obtained advanced assurance for EIS investment in 2015 and the directors believe the Company is still eligible for EIS investment.

 

Cairn Financial Advisers LLP is acting as the Aquis Stock Exchange Corporate Adviser with Stanford Capital Partners Ltd as broker.

The Company's admission document is available to view on its website   www.britishhoney.co.uk

Michael Williams, Chief Executive Officer, commented: "We are delighted by the considerable support from our new shareholders in this fundraise which was significantly oversubscribed. This IPO represents a landmark moment for BHC and will enable the business to grow both organically and through acquisitions as we continue to build our market share in the global spirits industry.

 

"I would like to thank all of our staff and business partners for their ongoing support and I would like to welcome our new shareholders to the register, we look forward to working with them during the next phase of our development."

 

Enquiries:

 

The British Honey Company	Tel: +44 (0)80 0368 7612
Michael Williams, Founder and CEO
Cairn Financial Advisers LLP (Aquis Stock Exchange Corporate Adviser)	Tel: +44 (0)20 7213 0880
Jo Turner / Liam Murray / Mark Rogers
Stanford Capital Partners (Broker)	Tel: +44 (0)20 3815 8880
Patrick Claridge / John Howes / Bob Pountney
IFC Advisory (PR)	Tel: +44 (0)20 3934 6630
Graham Herring / Florence Chandler

For further information, visit: www.britishhoney.co.uk

 

 

Notes to Editors

The British Honey Company is a UK based producer of spirits, honey and jams. It began trading in November 2014 initially focused on honey production and, later, expanding into honey infused spirits. The Company currently produces 13 honey products and 16 spirits including gin, vodka, rum and whiskey, many of which have won awards in the UK and abroad. These products are produced and stored in the Company's facilities in Worminghall, Buckinghamshire.

The Company's facilities provide it with a scalable platform from which the Directors plan to expand operations through organic growth and acquisition both in the UK and abroad. The Company has invested significantly in its infrastructure which includes, inter alia, a fully operational distillery with an electronic, computer-controlled, 1,000-litre capacity still and a bottling facility capable of processing the equivalent of approximately 1.5 million bottles per year. Further, the Company has developed proprietary software to manage the manufacturing process and sales which allows the Company, among other things, to trace single ingredients through to individual bottles of spirits or jars of honey. This meticulous approach has earned the Company accreditations from the Soil Association, for organic food certification, and from SALSA, for food safety. The Directors believe SALSA certification has only been awarded to approximately 39 producers of gin, vodka and whiskey in the UK.

As well as producing the Keepr's brand spirits, the distillery is an accredited, HMRC compliant, bonded warehouse for the storage of its own and third-party products. The Directors believe this provides the Company with significant financial and logistical advantages over many craft distilleries whilst also allowing it to provide an end-to-end distillation and bottling service to third party brands which it can do so within its existing spare capacity.

Board of Directors  

 

Sir Hugo Swire , aged 60 – Non-executive Chairman

Sir Hugo Swire was the Member of Parliament for East Devon from 2001 until retiring from Parliament in 2019. He has held various senior Ministerial offices for which he was created a Privy Counsellor and Knighted. Currently, he serves on a number of boards and has previous public company experience.  He is also currently Deputy Chairman of the Commonwealth Enterprise and Investment Council.  Prior to commencing his business career Sir Hugo was a commissioned officer in the Grenadier Guards.

 

Michael Williams , aged 77 – Chief Executive Officer

Mr Williams is an entrepreneur with a successful track record of returning shareholder value through public listings and M&A strategies. In the early part of his career he held senior positions in the United States for several major software houses including HP and Altos Computers.  On his return to the UK, he was Head of European sales for Cognos Inc before taking over Fletcher Dennis plc in partnership with Hillsdown Holdings. In partnership with investors he took over Cifer Plc and negotiated the reverse takeover by the Ferrari Group Ltd in 1989. In the 1990s he was one of the founders of Freecom.net plc – one of the first companies to become active in the E-commerce market. This business went on to list on AIM and carry out a number of acquisitions including Pegusus Accounting (£52m) and Systems Union Group PLC (£32m). Freecom.net plc (renamed as Systems Union) was sold to Golden Gate Private Equity for $460m. In 2002, Williams decided to take a career break and concentrate on his personal investments in a number of retail focused businesses. In 2014 he decided to return to an active business role by founding the Company due to his interest in bee keeping. Williams was instrumental in raising the early stage capital for the Company and has been its main driving force since inception.

 

Alistair Wallace , aged 46 – Finance Director

Mr Wallace qualified as an accountant with ACCA in 2000 and then as a Chartered Tax Adviser with the CIOT in 2002. He set up BKB Accountants Ltd in 2005 and now employs 25 people at two sites in Poole and Wimborne.  Mr Wallace is one of the foundering shareholders of the Company and has been involved since its incorporation, providing accountancy services and support throughout.

 

Robert Porter-Smith , aged 63 – Executive Director

Mr Porter-Smith is a successful entrepreneur who has worked in and founded a number of B2C and B2B businesses.  In particular, he was instrumental in the growth of Natural Balance Foods which was sold for £60m in 2015 to the Belgium-based biscuit maker Lotus Bakeries. He currently runs D2F which he founded in 2003. It is a digital fulfilment company that provides e-commerce solutions, tailored incentive programmes and distribution services to health clubs, sporting bodies such as Lords, Harlequin FC and Essex County Cricket Club as well as multinationals such as Diageo and Castrol. He is also an investor in a number of businesses including Truestart Coffee, which distributes coffee and RTD coffee products.

 

Wafic Saϊd , aged 80 – Non-executive Director

Mr Saϊd is a businessman, entrepreneur and philanthropist. He is the founder and Chairman of the Saïd Foundation and the founding benefactor of the Saïd Business School at Oxford University. He started his career in 1963 as a banker at UBS in Geneva and in the early 1970s he founded a construction business that specialised in turnkey construction projects in Saudi Arabia. This business was involved in building airports, desalination plants, housing and hospitals in Saudi Arabia in the 1970s and 1980s.  Since the 1980s, Saïd has focused on his investment and philanthropic activities.  In 1987 he founded Saïd Holdings Limited (SHL), a privately-held international investment company with assets in Europe, North America and the Far East, which is now the principal investment vehicle for the Saïd family interests. Saïd is a recipient of the Sheldon Medal, awarded by the University of Oxford, a Foundation Fellow of Somerville College, Oxford and a holder of the Grand Commandeur Ordre de Mérite du Cèdre of Lebanon and Ordre de Mérite of Morocco.

 

Philip Seers , aged 73 – Non-executive Director

Mr Seers was educated at Oundle School and Balliol College, Oxford. He joined Credit Suisse First Boston in 1968 where he was principally involved in the Eurobond market. In 1982 he co-founded Phoenix Securities which provided corporate finance services to the financial sector and private equity investment management, focussed on mid-market UK companies. Phoenix was acquired by Morgan Grenfell in 1987: it continued to operate as a separate entity and was reacquired by the partners in 1990. Donaldson, Lufkin & Jenrette acquired Phoenix Securities in 1997, as a platform for the development of its international corporate finance activities, and DLJ was itself acquired by Credit Suisse in 2000. Philip retired at this point and has since been a director of several large companies and an investor in early-stage companies.

 

Martin Riley , aged 65 – Independent Non-executive Director

Mr Riley was Chief Marketing Officer for the Pernod Ricard Group, the second biggest global spirits and wine company, until his retirement in 2015. He was President of the World Federation of Advertisers (2013/2015) – an international organisation based in Brussels which comprises major international companies and national advertising associations. He has an Honorary Doctorate in Business Administration from the University of Greenwich in recognition of his work with its business school. He is a board member of the Gin Guild and was Master of the Worshipful Company of Distillers (a City of London Livery Company) in 2019. He has 40 years' global drinks market experience, speaks fluent French and has worked in France, Belgium, Russia and Ireland. 

 

"Sophie" Guifang Luo , aged 51 – Non-executive Director

Mrs Luo represents the Company's Chinese investors on the Board and is the Company's ambassador in China although she is based in the UK.  Since 2015 she has been the Managing Director of a group of Chinese nurseries that has a joint venture with Craigclowan Prep. She also has family interests in several Chinese businesses in Shaanxi province including a green tea plantation in Ziyang from whom the Company purchases tea and the Kaiyuan shopping mall in Ankang.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXSFFESIESSELD

Close

×

Neville Registrars is delighted to welcome Pharis Energy Limited as the newest addition to its list of client companies.

Pharis Energy was established in early 2014, as The Steam Oil Production Company Ltd, by petroleum engineers.

Further information can be found on the Company's website: https://pharis.energy

 

Close

×

Neville Registrars is delighted to welcome FRP Advisory Group plc as the newest addition to its list of client companies.

FRP Advisory Group is a professional services firm established in 2010 which offers a range of advisory services to companies, lenders, investors and other stakeholders, as well as individuals.

Further information can be found on the Company's website: https://www.frpadvisory.com/

Close

×

Neville Registrars is delighted to welcome Incanthera plc as the newest addition to its list of client companies.

Incanthera is a revenue-generating, UK-based, oncology therapeutics company focusing on drug discovery and development of targeted medicines for the treatment of cancer.

Further information can be found on the Company's website: http://www.incanthera.com/

Close

×

RNS Number : 1136E

Integumen PLC

26 February 2020

 

AIM share code: SKIN

26 February 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Launch of ecowaterOS for real-time water monitoring, recovery, treatment and recycling  

 

Fin Murray promoted to COO, Paul Ryan to CSO

 

Expansion of sales and science team

 

Integumen announces the launch of ecowaterOS ("Ecological Water Operating System"), a green-tech data management eco-system that monitors and analyses water for bacteria contamination using artificial intelligence. ecowaterOS will provide a broad range of clients from water utilities to consumers with alerts as to the contamination of water supplies in real-time and the provision of services from a consortium of water decontamination solution providers.

 

ecowaterOS initial consortium members include:

 

· Rinocloud AI

· Acumen Software

· Nimbus Research Centre

· Cork Institute of Technology

· Cellulac plc

· Modern Water plc

· tcBB Resource Centre

 

Promotions and new hires:

Fionan (Fin) Murray, current director and Group Sales Director, becomes Chief Operations Officer, effective immediately and Paul Ryan is promoted to Chief Sales Officer across all divisions of Integumen as the demand for Integumen's services and subsequent growth requires further expansion of sales and scientific teams to cover multi-national clients on four continents.

 

Gerard Brandon CEO Integumen plc, Cellulac plc and ecowaterOS member commented:

"The consortium brings together multiple partners with a combined 32 years of tried and tested engineering skillsets added to smart AI cloud-based data analytic technologies and best-in-class engineering at commercial scale across the brewing, biofuel, chemical and wastewater industries.  With raising awareness of the direct impact of climate change across the world on systems vital to our wellbeing, ecowaterOS is a global game-changer for water monitoring, recovery, treatment and recycling."

 

Simon Humphrey, CEO of Modern Water commented:

"We are delighted to be able to provide the knowledge and expertise of our water monitoring services and supplies along with decontamination systems to the ecowaterOS multi-continental consortium. This unique platform of integrated water management systems, from contamination detection to decontamination is a world first end-to-end hi-tech solution to community, regional and continental-wide water shortages."

 

Contacts

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

 

 

Notes to Editors

 

About EcoSystemOS (www.ecosystemOS.com)

Developed by the Rinocloud division of Integumen plc, this is a consortium of partners operating a live dynamic water management system that delivers safe clear water from rivers to wastewater treatment plants using Artificial Intelligence to provide instant alerts from remote sensors direct to stakeholders. It continuously evolves, learns and improves by bringing together multiple existing and smart technologies to create efficient water and deliver environmental protection. Over-the-air monitoring keeps stakeholders constantly up to date with web and mobile alert applications adapted for each group.

 

About Integumen

Integumen is a vertically integrated physical and cloud-based company focused on commercialising AI test services for good and bad bacteria in skincare, healthcare and water.

 

Labskin is a test platform that scientifically proves the impact of skincare product claims for healthcare, life sciences, clinical research, pharmaceutical and cosmetics industries.

 

Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer clients valuable insights to support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector. 

 

ecowaterOS, or, Ecological Water Operating System, is a Greentech data management eco-system that monitors and analyses water for contamination using artificial intelligence, providing stakeholders, from water utilities to consumers, alerts to contamination of water supplies in real-time.

 

About Modern Water

Modern Water was established in 2006 to develop and commercialise water recovery technologies to counter water crisis problems arising from climate change and a growing global population. Having invested £20m over the last 14 years, the results comprise of a robust patent portfolio in cutting-edge technology, focussed on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.

 

About Cellulac plc

Cellulac is a group of companies with operations in Ireland and headquarters in the United Kingdom. Activities  range  from  the  production  of  natural  oils  and  biodegradable  plastic ingredients. The production division capabilities include process engineering, chemical engineering, biochemistry and polymer science. Cellulac has been privately funded since 2012 from laboratory to the commercial scale production of Omega 3 at a third-party facility in the UK. 

 

About the Acumen Software (Pty) Ltd :

Established in South Africa 2006 Acumen Software is a field service solution used to optimise workforce and asset management by empowering organisations with a user-friendly mobile software solution.

 

Acumen are present in South Africa and in Europe in the Republic of Ireland (through sister company Forcelink™ Solutions Limited), and represented throughout the world through strategic partners, these include Asia, North and South America, and Australasia.

 

About NIMBUS

The Nimbus is Ireland's leading research centre in cyber-physical systems & internet of things, undertaking research, innovation and development of technologies that address the real needs of industry, people and society. Dedicated to providing economic value to industry and sustainable solutions to societal problems with a mission to remain at the forefront of innovation in order to create and maintain an ecosystem of information and technology that will enrich society and transform industry.

 

About Cork Institute of Technology

Cork Institute of Technology's (CIT) Centre for Advanced Photonics & Process Analysis  (Cappa Group) team consisting of scientists with specialist spectroscopy qualifications covering various different projects ranging from fundamental research to applied industrial projects involving spectroscopic applications.

 

About tcbb RESOURCE – Irish Research Centre for Resource Efficiency CLG – www.tcbbresource.ie

tcbb RESOURCE is an Irish Government supported not-for-profit, test-bed for bio-based innovation – scale-up, demonstration and pilot technology for resource recovery and renewable gas and collaborates with higher-education research groups, enterprises and state agencies in publicly-funded programmes to support industry in the transition towards a low-carbon economy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDEAXASALPEEFA

Close